Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa ...

How Denali’s Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors

Denali Therapeutics announced it will present past and ongoing clinical and preclinical data from its Enzyme TransportVehicle (ETV) programs at the 22nd Annual WORLDSymposium in San Diego, ...

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming 22nd Annual ...